Cancer Research Technology
Log in Register
Menu

Anti-CD19, Recombinant [BU12]

Invented at University Of Birmingham

Info

Catalogue Number 153262
Applications FACS IHC IP
Antigen/Gene or Protein Targets CD19
Synonyms CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
Reactivity Human
Relevance CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
Host Mouse
Immunogen Human EB-4 Burkitt's lymphoma cell line
Subclass IgG1
Formulation PBS
Concentration 1mgml-1
Research Area Immunology
Notes Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

Five products based on this clone:
- Anti-CD19 [BU12], Mouse IgG1, Kappa
- Anti-CD19 [BU12], Rabbit IgG, Kappa
- Anti-CD19 [BU12], Human IgG4-S228P, Kappa
- Anti-CD19 [BU12], Human IgG1, Kappa
- Anti-CD19 [BU12], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Original hybridoma first published in: Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.


Add a reference

References: 1 entry

Original hybridoma first published in: Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor